RU2395503C2 - Лекарственные средства, содержащие n-сульфамоил-n'-арилпиперазины, предназначенные для профилактики или лечения ожирения и связанных с ним состояний - Google Patents

Лекарственные средства, содержащие n-сульфамоил-n'-арилпиперазины, предназначенные для профилактики или лечения ожирения и связанных с ним состояний Download PDF

Info

Publication number
RU2395503C2
RU2395503C2 RU2006144812/04A RU2006144812A RU2395503C2 RU 2395503 C2 RU2395503 C2 RU 2395503C2 RU 2006144812/04 A RU2006144812/04 A RU 2006144812/04A RU 2006144812 A RU2006144812 A RU 2006144812A RU 2395503 C2 RU2395503 C2 RU 2395503C2
Authority
RU
Russia
Prior art keywords
group
substituted
substituents
trifluoromethyl
formula
Prior art date
Application number
RU2006144812/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2006144812A (ru
Inventor
Йохен АНТЕЛЬ (DE)
Йохен Антель
Питер-Колин ГРЕГОРИ (DE)
Питер-Колин Грегори
Уве РАЙНЕККЕР (DE)
Уве РАЙНЕККЕР
Михаэль ВУРЛ (DE)
Михаэль ВУРЛ
Уве ШЁН (DE)
Уве ШЁН
Харальд ВАЛЬДЕКК (DE)
Харальд ВАЛЬДЕКК
Михаэль ФИРНГЕС (DE)
Михаэль Фирнгес
Даниа РАЙХЕ (DE)
Даниа Райхе
Original Assignee
Зольвай Фармасьютиклз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зольвай Фармасьютиклз Гмбх filed Critical Зольвай Фармасьютиклз Гмбх
Publication of RU2006144812A publication Critical patent/RU2006144812A/ru
Application granted granted Critical
Publication of RU2395503C2 publication Critical patent/RU2395503C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2006144812/04A 2004-05-19 2005-05-18 Лекарственные средства, содержащие n-сульфамоил-n'-арилпиперазины, предназначенные для профилактики или лечения ожирения и связанных с ним состояний RU2395503C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57223604P 2004-05-19 2004-05-19
EP04102210 2004-05-19
EP04102210.4 2004-05-19
US60/572,236 2004-05-19

Publications (2)

Publication Number Publication Date
RU2006144812A RU2006144812A (ru) 2008-06-27
RU2395503C2 true RU2395503C2 (ru) 2010-07-27

Family

ID=34969508

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006144812/04A RU2395503C2 (ru) 2004-05-19 2005-05-18 Лекарственные средства, содержащие n-сульфамоил-n'-арилпиперазины, предназначенные для профилактики или лечения ожирения и связанных с ним состояний

Country Status (11)

Country Link
EP (1) EP1750712A2 (pt)
JP (1) JP2007538054A (pt)
CN (1) CN1997370B (pt)
AU (1) AU2005244450B2 (pt)
BR (1) BRPI0510137A (pt)
CA (1) CA2567166A1 (pt)
IL (1) IL178903A0 (pt)
MX (1) MXPA06013299A (pt)
NO (1) NO20065835L (pt)
RU (1) RU2395503C2 (pt)
WO (1) WO2005110413A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1866298A2 (en) 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
CA2637449A1 (en) * 2006-01-23 2007-07-26 F. Hoffmann-La Roche Ag Cyclohexyl sulfonamide derivatives having h3 receptor activity
JP5301465B2 (ja) 2007-01-25 2013-09-25 バーバ・ファーマシューティカルズ・リミテッド インスリン抵抗性改善薬および治療方法
RU2539591C2 (ru) * 2009-04-22 2015-01-20 Аксикин Фармасьютикалз, Инк. Антагонисты арилсульфонамида ccr3
RU2445963C2 (ru) * 2010-07-09 2012-03-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая противодиабетическая композиция
ES2753386T3 (es) 2013-03-13 2020-04-08 Forma Therapeutics Inc Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etano-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer
GB201410817D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D Therapeutic agents
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2748125A (en) * 1954-04-26 1956-05-29 American Cyanamid Co 1-substituted-4-sulfamylpiperazine and method of preparing the same
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
WO1995009151A1 (en) * 1993-09-28 1995-04-06 Ciba-Geigy Ag Acylated sulphonamides as insecticides and acaricides
SU1646258A3 (ru) * 1989-02-08 1996-02-10 Институт биохимии Литовской АН 5-аминонафталин-1-сульфамиды в качестве детектируемых групп субстратов для флюоресцентного анализа пептидаз
WO1998032748A1 (en) * 1997-01-23 1998-07-30 F. Hoffmann-La Roche Ag Sulfamide-metalloprotease inhibitors
WO2003075929A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2030116A1 (en) 1969-01-02 1970-10-30 Sandoz Sa Herbicide compositions and prepn
US3709677A (en) * 1969-06-25 1973-01-09 Sandoz Ag N-substituted sulfamoyl compounds useful as herbicides
DE4025387A1 (de) 1990-08-10 1992-02-13 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als reagenzien
DE10035227A1 (de) 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
DE60325051D1 (de) * 2002-06-06 2009-01-15 Boehringer Ingelheim Pharma SUBSTITUIERTE 3-AMINO-THIENO(2,3-b)PYRIDINE-2-AMIDE UND HERSTELLUNGSVERFAHREN SOWIE DEREN VERWENDUNG
WO2005005382A2 (en) * 2003-07-02 2005-01-20 Cytokinetics, Inc. Compounds, compositions and methods
EP2311827A1 (en) 2004-08-28 2011-04-20 AstraZeneca AB Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2748125A (en) * 1954-04-26 1956-05-29 American Cyanamid Co 1-substituted-4-sulfamylpiperazine and method of preparing the same
SU1646258A3 (ru) * 1989-02-08 1996-02-10 Институт биохимии Литовской АН 5-аминонафталин-1-сульфамиды в качестве детектируемых групп субстратов для флюоресцентного анализа пептидаз
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
WO1995009151A1 (en) * 1993-09-28 1995-04-06 Ciba-Geigy Ag Acylated sulphonamides as insecticides and acaricides
WO1998032748A1 (en) * 1997-01-23 1998-07-30 F. Hoffmann-La Roche Ag Sulfamide-metalloprotease inhibitors
WO2003075929A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase

Also Published As

Publication number Publication date
EP1750712A2 (en) 2007-02-14
WO2005110413A2 (en) 2005-11-24
JP2007538054A (ja) 2007-12-27
BRPI0510137A (pt) 2007-10-02
IL178903A0 (en) 2007-03-08
AU2005244450B2 (en) 2010-08-19
NO20065835L (no) 2007-02-16
CA2567166A1 (en) 2005-11-24
CN1997370B (zh) 2011-06-01
AU2005244450A1 (en) 2005-11-24
CN1997370A (zh) 2007-07-11
WO2005110413A3 (en) 2006-07-13
RU2006144812A (ru) 2008-06-27
MXPA06013299A (es) 2007-02-02

Similar Documents

Publication Publication Date Title
US9822092B2 (en) ArylSulfonamide-based matrix metalloprotease inhibitors
RU2442773C2 (ru) Новые n-сульфамоилпиперидинамиды, предназначенные для профилактики или лечения ожирения и родственных патологических состояний
RU2395503C2 (ru) Лекарственные средства, содержащие n-сульфамоил-n'-арилпиперазины, предназначенные для профилактики или лечения ожирения и связанных с ним состояний
US7772225B2 (en) N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions
US7547708B2 (en) N-sulfamoyl-N′-benzopyranpiperidine compounds and uses thereof
US20050261292A1 (en) Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions
EP1951725B1 (en) N-sulfamoyl-n -benzopyranpiperidines as inhbitors of carbonic anhydrases
WO2009153261A1 (en) HYDROXYPHENYL-SUBSTITUTED PYRROLO[2,3d]PYRIMIDINE DERIVATIVES, PROCESSES AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS
US20100152285A1 (en) Flavononol Renin Inhibitor Compounds and Methods of Use Thereof
KR20070022322A (ko) Ｎ­설파모일­ｎ′­아릴피페라진을 함유한 비만 및 관련된상태의 예방 또는 치료용 의약
HK1101274A (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
HK1123791A (en) Novel n-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions
WO2007053406A1 (en) Combinations of antihypertensive and cholesterol lowering agents
WO2007051007A2 (en) Combination of antihypertensives with cholesterol-lowering agent
HK1123546A (en) N-sulfamoyl-n'-benzopyranpiperidines as inhbitors of carbonic anhydrases

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120519